The results are looking good for the first-round of human testing for Oral-lyn, Generex's flagship product. The oral insulin, delivered into the body through the oral cavity (with no deposit in the lungs), is as effective as injected insulin.

The efficacy of Oral-lyn for controlling blood sugar was decidedly as good as multiple insulin injections. The research found that regular insulin and Generex Oral-lyn had similar effects on lowering blood sugar in subjects with type 1 diabetes. The subjects received twice-daily insulin analogue for basal coverage. So this might rewind some of us old timers to the days long-gone where we could get by with two shots. Period. If Oral-lyn makes it to the local pharmacies - maybe mealtime corrections could be easy to swallow. Praise patient compliance!

On an even more impressive note - it looks like the mucosal membrane in the lungs is giving Exubera negative challenges to overcome. Perhaps Oral-lyn will come out looking a little more pristine in this capacity, since it doesn't go anywhere near the lung membranes. I'm not in favor of diabusiness - but for crying out loud - I'd like to see some companies start working for their money. Generex is one of those companies with the Big Idea!

When TIME magazine does a piece on your plight - it's definitely gaining public interest. The fact that 1 in 3 people affected by Type 1 diabetes manipulate their insulin to lose weight is an eye-opening statistic. This lethal coping mechanism is termed diabulemia and a major national TV show is seeking diabulmics for a "sensitive, accurate portrayal of the condition" - at least that is what they told me.

I volunteered myself for the interview. I've struggled with diabulemia for the past 15 years until I did something a doctor would NEVER recommend. I called the station back - it was CNN. I divulged what a day in the life was like when I practiced diabulemia -- and I was good at it! When I told the interviewer that I noticed a world of difference when I changed my insulin from human synthetic to natural animal, she was surprised (so was my doctor). The key to mitigating my angst with insulin was getting the message to my brain at the same time the rest of my body was getting the glucose. This is less effective in newer insulin analogues. Big Pharma does not profit by selling natural vertebrate insulin even if it is better for hormonal response in suppressing appetite and preventing your body from entering ketoacidosis (DKA). Big Pharma profits if they own the patent for the specific insulin analogue you use. In my land of milk and honey - I realized Big Pharma is not my mom, not my dad and not my best friend. Big Pharma is not personal -- Big Pharma is business. So I took my business elsewhere because I didn't like the way Big Pharma was handling my business.

I don't mind explaining my abusive relationship with insulin if it helps anybody struggling with diabulemia. It's a shameful thing but it doesn't have to be. It's controversial but it's all true. For those of you considering your 15 minutes for diabulemia -- don't be concerned about your privacy. The TV show is planning to shoot the interview in shadow. If you wish to learn more about contributing to this documentary, please see The Sugar Shock.

Mad Money is a stock show on CNBC hosted by Jim Cramer - a well-known iron fist on Wall Street. He has a following of stock enthusiasts who regard his recommendations (buy or sell) as gospel. Why is he so good at what he does? He just wants to help you make money.

And to this end -- the reason I bring Cramer's passionate drive to The Diabetes Blog is simple: last week he called Novo Nordisk as a SELL. Cramer said he's beginning to worry about a backlash on drug stocks. He advised that viewers should not be greedy and should take gains in Novo Nordisk (NVO).

Perhaps the NY Times article raised some eyebrows at Big Pharma. It appears doctors are receiving handsome gifts and stipends for handing out samples of drugs that were not all that safe for most patients. The payments give physicians an incentive to prescribe the medicines at levels that might increase patients' risks of heart attacks or strokes. In light of this blood curdling synopsis Novo got a dishonorable mention. Novo Nordisk professes to operate their company in two parts: biopharmaceuticals and Diabetes Care. The Diabetes Care segment provides insulin analogues, human insulin and insulin-related products, and oral antidiabetic drugs.

The cross examination of the C-peptide disappearing act and mysterious insulin auto-antibodies appearing where they shouldn't is just getting started. Thanks for making them sweat, Cramer!

In the next 3 to 5 years, we will have a new generation of control upon us providing continuous glucose monitoring. Some of these marvelous technologies will not require a drop of blood, while others will embody the tried-and-true stick-to-itiveness we all know and loathe.

Please join me as we browse the isles of things to come (and things now available) for continuous glucose monitoring.

The DexCom STS Continuous Glucose Monitoring System is a glucose sensor that reports glucose values every 5 minutes for up to 72 hours. The sensor is inserted in the abdomen. After a 2 hour start-up period, the STS System is calibrated with 2 fingerstick measurements taken by a traditional glucose meter. Checkout Amy Tenderich's review on Diabetes Mine of the DexCom Continuous Glucose Monitoring Sytem.

MiniMed Medtronic has 3 different versions: the Gold, the Guardian RT, and the Paradigm Real-Time Continuous Monitor.

Menarini GlucoDay S is a device worn by the patient for the continuous monitoring of glucose in the subcutaneous interstitial fluid. Monitoring is performed via insertion in the abdominal region of a microfibre for dialysis having the diameter of a human hair. Inside the microfibre a solution transports the patient's glucose to a biosensor within the instrument.

M-Biotech Glucose Biosensor is a minimally invasive implantation for painless and convenient monitoring. The key feature of our efficient Glucose Biosensor is the combination of a glucose-sensitive hydrogel and a miniature pressure sensor. Glucose-responsive hydrogels are biocompatible materials that either swell or contract when the glucose concentrations change in the body fluid surrounding the hydrogel.

The PreciSense System includes a microcapsule placement unit and a light detecting non-invasive reader unit. The microcapsule placement unit poses the right dose of glucose-responding microcapsules in the upper layer of the skin, painlessly. The glucose assay components in the microcapsules generate a fluorescence signal that corresponds to the glucose level. The non-invasive reader unit monitors this glucose binding event through FRET, Fluorescence Resonance Energy Transfer, which is directly related to the concentration of glucose.

Sensors for Medicine and Science glucose sensor is implanted under the skin in a short outpatient procedure. The sensor automatically measures interstitial glucose every few minutes, without any user intervention. The sensor implant will communicate wirelessly with a small external reader.

Synthetic Blood Implanted Glucose Biosensor claims to offer significantly more accurate glucose readings in a range of 30-500 mg/dl. The implanted Glucose Biosensor continuously monitors blood glucose without the need for finger sticks. The most accurate glucose monitor available, the implanted biosensor can be programmed to monitor blood glucose according to a predetermined schedule, thus eliminating problems of patient compliance. The sensor alarms for dangerous, life threatening conditions such as hypoglycemia.

GlucoLight Corporation is developing a low-cost non-invasive blood glucose monitor for home use by diabetic patents. GlucoLight's unique optical approach, microScatterTM (microscatter) technology, is based on patented technologies in the area of Optical Coherence Tomography (OCT) and Low Coherence Interferometry (LCI). There is a working prototype with published clinical data on healthy volunteers.

The GlucoWatch G2 Biographer was approved to detect glucose level trends and track patterns in people with diabetes. It must be used along with conventional blood glucose monitoring of blood samples. The device, which looks like a wristwatch, pulls body fluid from the skin using small electric currents. It can provide six measurements per hour for 13 hours. (See David Mendosa's review).

Diabetes is making a name for itself and it's spreading like wildfire. Politicians are uniting to build a $120 million campaign to educate diabetics to prevent the spread of the disease and its complications.

Senator Clinton criticizes the reaction to the problem, rather than taking measures to prevent it from occurring. She questions why current money is unquestionably $pent on treating complications from diabetes -- such as amputations and dialysis. Good point, Senator. Ask Bush if he's got any friends up at Eli Lilly. A good answer can always be found in a temporary restraining order. She and fellow politicians propose more money be spent on programs for weight-loss, nutrition education and other preventive efforts to best curtail the growing number of diabetics in the United States.

The legislation proposed would provide $90 million to the Centers for Disease Control and Prevention's Division of Diabetes Translation for diabetes surveillance, research and educational activities. It would also allot $30 million for three four-year projects that would examine how best to translate diet and exercise interventions into effective clinical practice.

Mike Huckabee is a politician, an award winning "Health Crusader", and a successful loser of over 100 pounds.

After being diagnosed with type 2 diabetes in 2002, his doctor gave him two oral meds and a stern warning. His doctor told him the condition of his health, the lifestyle he leads and the stress level of his job would likely put him six feet under within 10 years. At 48 years of age he was one of the youngest governors in the Nation. He knew he could win this fight -- and he did. After losing 110 pounds, the Governor of Arkansas reversed his diabetes and serendipitously assumed a role in the war against obesity.

It took a sobering message, dedication and commitment to bring Mike the healthy lifestyle he enjoys today. On the next dLifeTV, learn how Governor Mike Huckabee is winning the battle against diabetes. dLifeTV airs every Sunday on CNBC at 7PM Eastern, 6PM Central and, 4PM Pacific.

Luke Branquinho, a World Champion Steer Wrestler, reveals his tricks to triumphing over diabetes on national television this coming Sunday. Learn how this tough cowboy has lassoed diabetes to the ground along with angry steers putting him on top of America's grueling professional rodeo circuit.

Luke is an inspirational athlete who has motivated other diabetics to follow their dreams. On an interview he gave to ESPN Prorodeo, he shares his words of encouragement, for one little girl in California. "She was only 5 or 6," Branquinho said. "And she was kind of down because she'd just gotten diagnosed with diabetes. She didn't think she could go play with her friends. I told her no way is it going to stop her." I know ladies- he's passionate about his work, a World Champion, and a sight for sore eyes (not to mention 6'0 tall). Alas, he's very much spoken for by his lovely wife, Lindsay.

Luke takes center arena this Sunday (September 17, 2006) on dLifeTV on CNBC at 7:00PM ET. Branquinho is passionate about facing the challenges that allow him to come out of the chute to wrestle steers, shots and diabetes. Luke reminds us that the spirit of the Old West is alive and well, and embodied in this modern day cowboy who travels the road, faces daily struggles and keeps the American spirit shining brightly.

Visit dLife for more on this week's show---It's all about diabetes.